Abbreviated MRI Protocol Can Exclude Malignancy After Mammo

This article originally appeared here.
Share this content:
Abbreviated MRI Protocol Can Exclude Malignancy After Mammo
Abbreviated MRI Protocol Can Exclude Malignancy After Mammo

WEDNESDAY, Sept. 30, 2015 (HealthDay News) -- An abbreviated magnetic resonance imaging (MRI) protocol can exclude malignancy in women with suspicious X-ray mammography screening, according to a study published online Sept. 29 in Radiology.

Sebastian Bickelhaupt, M.D., from the German Cancer Research Center in Heidelberg, and colleagues conducted a prospective study involving 50 women with suspicious screening X-ray mammograms. The authors sought to examine the ability of a diagnostic abbreviated MRI protocol consisting of maximum intensity projections (MIPs) from diffusion-weighted imaging with background suppression (DWIBS) and unenhanced morphologic sequences to help predict the likelihood of malignancy. Participants underwent two abbreviated protocols based on MIPs and the findings were compared with those of the full diagnostic protocol and histopathologic findings. Twenty-four participants had a breast carcinoma.

The researchers found that the sensitivity was 0.92, specificity 0.94, negative predictive value (NPV) 0.92, and positive predictive value (PPV) 0.93 for DWIBS. The mean reading time was 29.7 seconds; in the absence of suspicious findings on the DWIBS MIPs, the mean reading time was less than three seconds. With the second abbreviated protocol (subtraction images from the first post-contrast and the unenhanced series), the sensitivity, specificity, NPV, and PPV were 0.85, 0.90, 0.87, and 0.89, respectively; the mean reading time was 29.6 seconds.

"Unenhanced diagnostic MR imaging (DWIBS mammography), with an NPV of 0.92 and an acquisition time of less than seven minutes, could help exclude malignancy in women with suspicious X-ray screening mammograms," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »